● In early May, the RWE report was published in the Infectious Disease Open Forum Journal, demonstrating the effectiveness of the quadrivalent cell-based influenza vaccine compared to the fertilized egg-based vaccine in preventing test-confirmed influenza1.
● In three consecutive US influenza seasons (2017-2020), QIVc was consistently more than 10% higher than rVE compared to QIVe1
CSL Seqirus, a leading global influenza prevention company, published a new version of its cellular quadrivalent influenza vaccine (QIVc) in the journal “Open Forum Infectious Diseases (OFID)” published in May (RWE) trials announced .
During the three-year influenza epidemic period from 2017 to 2020 in the United States, CSL Securus’ cell-based quadrivalent influenza vaccine (QIVc) was more effective than fertilized egg-based quadrivalent influenza vaccine, according to the study (RWE). (QIVe). It was found that the flu prevention effect was greatest in the age group 4 to 64 years.1
The study analyzed data from 31,824, 33,388, and 34,398 patients during the 2017-18, 2018-19, and 2019-201 influenza seasons, respectively, resulting in a 14.8% increase in QIVc compared to QIVe in each season, and found showed an increase of 12.5%. and a relative vaccine efficacy (rVE) greater than 10.0%.1
“This study demonstrates the value of RWE in providing valuable information about the effectiveness of flu vaccines,” said Alicia N. Stein, director of the Center for Outcomes Research and Epidemiology at CSL Securus of data collected over three consecutive seasons, I think It is very significant that the efficacy of the cell-based quadrivalent influenza vaccine was consistently superior to that of the fertilized egg-based vaccine.”
Meanwhile, flu vaccines produced based on fertilized eggs may undergo egg-adapted changes during the manufacturing process as the virus adapts to fertilized eggs. In this case, there may be a discrepancy between the strain included in the fertilized egg flu vaccine and the actually prevalent strain, which could weaken the vaccine recipient’s immune response to the prevalent virus and reduce the effectiveness of the vaccine.2, 3
In this regard, Stefan Merlo, vice president of business development at CSL Securus, said: “Cell-based influenza vaccines such as QIVc can improve vaccine effectiveness by eliminating fertilized eggs during the manufacturing process, thus preventing virus mutations4 due to the process of adaptation to fertilized eggs.“CSL Securus is committed to reducing the burden of influenza and, in fact, is leading the way in increasing the effectiveness of vaccines and improving public health through innovative technologies such as cells”.
1. Imran, Mahrukh et al. “Relative Effectiveness of Quadrivalent Cell-Based Versus Egg-Based Influenza Vaccines in Adults During the 2019–2020 Influenza Season in the United States.” Open Infectious Diseases Forum vol. 9.10 diac532. October 12, 2022, doi:10.1093/ofid/ofac532
2. Peck, Heidi et al. “Better isolation of influenza viruses in qualified cells improves the likelihood of well-matched vaccines.” Vaccines NPJ vol. 6.1 149. December 9, 2021, doi:10.1038/s41541-021-00415-3
3. Liu, Feng et al. “Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses after influenza vaccination.” The Journal of Clinical Investigations Vol. 131.8 (2021): e146138. doi:10.1172/JCI146138
4. Chua, Huiying et al. “The use of test-negative controls to monitor vaccine efficacy: a systematic review of methodology.” Epidemiology (Cambridge, Mass.) vol. 31.1 (2020): 43-64. doi:10.1097/EDE.0000000000001116
#CSL #Securus #Demonstrates #Superior #Efficacy #Compared #Fertilized #Egg #Vaccines #Consecutive #Seasons #CellBased #Quadrivalent #Influenza #Vaccine #RWE
